Skip to main content
. Author manuscript; available in PMC: 2009 Apr 1.
Published in final edited form as: Eur J Pharm Sci. 2008 Jan 31;33(4-5):371–379. doi: 10.1016/j.ejps.2008.01.006

Table 2.

Pharmacokinetic parameters of 6-β-naltrexol (NTXOL) after application of a gel formulation containing either CB-NTXOL-BUPOH or 6-β-naltrexol base (control). Data is represented as mean (±S.D.). n = 5 for NTXOL and n = 6 for CB-NTXOL-BUPOH

Parameter NTXOL NTXOL from CB-NTXOL-BUPOH
AUC0-48(ng/ml*h) 66.4 ± 7.9 282.0 ± 14.5
Cmax(ng/ml) 1.5 ± 0.2 6.6 ± 0.4
Tmax (h) 28.1 ± 1.5 10.1 ± 0.9
Tlag (h) 5.1 ± 0.7 5.0 ± 1.1
Observed CSS(ng/ml) 1.3 ± 0.5 6.4 ± 0.9
Predicted CSS(ng/ml)* 0.2 ± 0.1 0.7 ± 0.3
Enhancement factor 1 5.3
*

Predicted from in vitro human skin diffusion data